+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Benign Prostatic Hyperplasia Therapeutics Market by Dosage Form, Distribution Channel, End User, Therapy Type - Global Forecast to 2030- Product Image
Benign Prostatic Hyperplasia Therapeutics Market by Dosage Form, Distribution Channel, End User, Therapy Type - Global Forecast to 2030- Product Image
Sale

Benign Prostatic Hyperplasia Therapeutics Market by Dosage Form, Distribution Channel, End User, Therapy Type - Global Forecast to 2030

  • PDF Icon

    Report

  • 194 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6081737
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Understanding the Evolving BPH Therapeutics Landscape

The landscape of benign prostatic hyperplasia (BPH) therapeutics has evolved dramatically over the past decade, driven by demographic shifts, technological advancements, and changing patient expectations. As populations age globally, the prevalence of BPH has risen, placing greater demand on healthcare systems to deliver effective, patient-centric treatments. Clinicians and stakeholders now face the dual challenge of addressing symptomatic relief rapidly while minimizing long-term risks associated with pharmacologic interventions. In response, pharmaceutical companies have intensified research into novel mechanisms of action, refining existing therapies and exploring combination approaches that promise enhanced outcomes.

This executive summary provides a concise yet comprehensive overview of the current state of the BPH therapeutics market, highlighting transformative trends, regulatory impacts, segmentation dynamics, regional variations, competitive landscapes, and actionable strategies for industry leaders. By synthesizing the latest insights and data, we aim to equip decision-makers with the contextual understanding they need to identify growth corridors, anticipate market disruptions, and make informed investments.

Major Shifts Driving BPH Treatment Advancements

Recent years have witnessed transformative shifts in the BPH treatment paradigm, moving beyond symptom management toward precision care and long-term disease modification. Advances in molecular biology have unveiled key drivers of prostatic enlargement, spawning targeted therapies that inhibit 5-alpha reductase enzymes with greater specificity. Concurrently, the proliferation of minimally invasive surgical techniques and the integration of digital health platforms have empowered urologists to tailor treatment pathways in real time, optimizing therapeutic efficacy and patient adherence.

Moreover, patient preferences have reshaped market dynamics, with growing acceptance of phytotherapeutics and combination regimens that promise synergistic benefits. Telemedicine adoption has accelerated follow-up care and symptom monitoring, reinforcing the importance of real-world evidence in therapy evaluation. Regulatory agencies are also recalibrating approval frameworks to streamline the entry of innovative compounds, fostering a more competitive environment. Collectively, these shifts underscore a market in flux, where agility and foresight will distinguish the frontrunners from the laggards.

Assessing the Effect of 2025 US Tariffs on BPH Drugs

The United States government’s implementation of new tariffs in 2025 has introduced critical cost pressures across the pharmaceutical supply chain, with significant repercussions for BPH therapeutics. Import duties applied to active pharmaceutical ingredients have elevated production costs for manufacturers reliant on global sourcing, triggering strategic reassessments of supply chain optimization. In response, companies have pursued nearshoring strategies, locating key manufacturing operations closer to end markets to mitigate tariff exposure and reduce transit complexities.

Price adjustments have followed, prompting payers and healthcare providers to renegotiate procurement contracts. In some cases, formulary placements have shifted in favor of locally produced generics and biosimilars that circumvent tariff burdens. Nonetheless, innovators have leveraged the tariff challenge as an impetus to underscore the value proposition of differentiated therapies, highlighting long-term cost savings through reduced hospitalizations and improved patient quality of life. As the market adapts to these economic headwinds, stakeholders must balance tariff-driven constraints with the imperative to sustain research and development investments.

In-Depth Insights into Market Segmentation Dynamics

A nuanced understanding of market segmentation provides invaluable guidance for product development, marketing strategies, and commercial investments within the BPH therapeutics sector. Analysis by dosage form reveals the distinct trajectories of capsule, liquid, and tablet formulations, each aligned to patient preferences and pharmacokinetic profiles. Tablets remain the cornerstone for established agents, while capsules and liquid suspensions gain traction among patients prioritizing ease of administration and flexible dosing.

Distribution channel dynamics further shape market accessibility and patient reach. E-commerce platforms have emerged as vital conduits for direct-to-patient fulfillment, bypassing traditional intermediaries, while hospital pharmacies continue to anchor dispensing in acute care settings. At the same time, retail pharmacies maintain their role as convenient touchpoints for chronic therapy adherence.

End-user segmentation underscores divergent care pathways, spanning homecare environments where self-administration and telemonitoring dominate, to hospital settings that facilitate acute interventions and specialized urology clinics that offer integrated diagnostic and therapeutic services. Insights into therapy type segmentation illuminate the competitive interplay among 5-alpha reductase inhibitors, alpha blockers, combination therapies, and phytotherapeutics. Within the 5-alpha reductase inhibitor class, agents such as dutasteride and finasteride serve distinct efficacy and safety profiles. The alpha blocker category encompasses alfuzosin, doxazosin, tamsulosin, and terazosin, each varying in receptor selectivity. Combination strategies leverage dutasteride plus tamsulosin for synergistic relief, while phytotherapeutic options like beta-sitosterol, pygeum, and saw palmetto cater to patients seeking natural interventions.

Regional Variations Shaping BPH Therapeutics Adoption

Regional perspectives reveal stark contrasts in BPH therapeutics adoption and market maturity. In the Americas, robust healthcare infrastructures and established reimbursement frameworks support widespread uptake of advanced pharmaceutical therapies and minimally invasive procedures. The emphasis on value-based care and patient-reported outcomes has accelerated interest in combination regimens that deliver comprehensive symptom relief.

Within Europe, Middle East & Africa, regulatory harmonization across the European Union facilitates cross-border distribution, while emerging economies within the Middle East and Africa present growth opportunities driven by improving healthcare access and awareness initiatives. In these regions, the balance between cost-effective generics and premium branded offerings shapes market entry strategies.

The Asia-Pacific region exhibits a heterogeneous landscape, with highly developed markets in Japan and Australia contrasting with rapidly evolving healthcare systems in China and India. High patient volumes, government-led screening programs, and rising disposable incomes underpin the adoption of novel pharmacologics and phytotherapeutics alike. Stakeholders must navigate diverse regulatory regimes and local competition to capitalize on the region’s expansive potential.

Competitive Dynamics and Leading Industry Players

The competitive landscape of BPH therapeutics is defined by the strategic maneuvering of leading pharmaceutical and biotech firms seeking to expand their foothold in a high-value market. Key players have differentiated through innovative formulations, robust clinical evidence, and targeted marketing campaigns that emphasize real-world outcomes. Companies with comprehensive portfolios spanning established pharmacologics and emerging therapies are well positioned to capture incremental market share.

Strategic alliances and licensing agreements have increased in frequency, allowing organizations to co-develop or co-market compounds that address unmet clinical needs. Meanwhile, smaller biotechs focus on niche opportunities, pursuing first-to-market approval for novel mechanisms of action or specialized patient populations. In parallel, generic manufacturers leverage economies of scale to offer cost-competitive alternatives once patents expire, compelling innovators to accelerate lifecycle management initiatives and pursue label expansions. This dynamic interplay of innovation, collaboration, and competition continues to elevate standards of care for patients with BPH.

Strategic Recommendations for Market Leadership

To thrive in the evolving BPH therapeutics market, industry leaders must adopt a multifaceted strategy that aligns innovation with operational excellence. First, investments in differential formulations and novel delivery systems will be critical to meet shifting patient preferences and enhance adherence. Simultaneously, stakeholders should pursue targeted partnerships and licensing deals to accelerate pipeline diversification and mitigate development risks.

Second, optimizing supply chain resilience through regional manufacturing hubs and strategic raw material sourcing can offset economic headwinds such as tariffs and currency volatility. Companies should integrate advanced analytics and real-time risk monitoring into procurement frameworks to maintain continuity. Third, embedding digital health solutions into patient engagement models will create value-added experiences, enabling proactive symptom tracking and teleconsultations that strengthen brand loyalty. Finally, aligning commercial strategies with regional reimbursement policies and health authority guidelines will maximize market access and ensure sustainable growth across diverse geographies.

Robust Methodology Underpinning Our Analysis

This analysis draws upon a rigorous, multi-dimensional research framework designed to deliver comprehensive market insights. Primary research involved in-depth interviews with urologists, healthcare payers, and industry executives to capture firsthand perspectives on treatment paradigms and unmet needs. Secondary research encompassed a thorough review of scientific publications, regulatory filings, company financial reports, and proprietary databases to triangulate market data and validate assumptions.

Quantitative modeling employed a bottom-up approach to analyze therapy adoption patterns and competitive dynamics, while qualitative assessments evaluated innovation pipelines and regulatory landscapes. Granular segmentation analyses examined variations across dosage forms, distribution channels, end-user settings, and therapy categories. Regional analyses incorporated economic indicators and healthcare infrastructure metrics to contextualize growth opportunities. Throughout the process, stringent quality controls and peer reviews ensured that findings reflect the most current and accurate market intelligence available.

Concluding Perspectives on BPH Therapeutics Trends

The trajectory of BPH therapeutics is marked by continuous innovation and strategic adaptation. As the market expands, stakeholders must harmonize research priorities with patient-centric outcomes, regulatory shifts, and economic pressures. Precision therapies targeting molecular pathways, coupled with digital integration, will redefine standard of care. Concurrently, a nuanced understanding of segmentation and regional dynamics will guide tailored commercial strategies that maximize uptake and payer acceptance.

Collaborative ventures between established industry players and emerging biotechs will accelerate the introduction of groundbreaking treatments, while lifecycle management and generics competition will sustain affordability. Ultimately, organizations that balance visionary R&D investments with agile operational frameworks will lead the next wave of growth, delivering meaningful improvements in patient quality of life and healthcare system efficiencies.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Dosage Form
    • Capsule
    • Liquid
    • Tablet
  • Distribution Channel
    • E-Commerce Platforms
    • Hospital Pharmacies
    • Retail Pharmacies
  • End User
    • Homecare
    • Hospitals
    • Urology Clinics
  • Therapy Type
    • 5-Alpha Reductase Inhibitors
      • Dutasteride
      • Finasteride
    • Alpha Blockers
      • Alfuzosin
      • Doxazosin
      • Tamsulosin
      • Terazosin
    • Combination Therapies
      • Dutasteride Plus Tamsulosin
    • Phytotherapeutics
      • Beta-Sitosterol
      • Pygeum
      • Saw Palmetto
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • AbbVie Inc.
  • Merck & Co., Inc.
  • Astellas Pharma Inc.
  • Johnson & Johnson
  • Pfizer Inc.
  • Sanofi S.A.
  • Bayer AG
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Novartis AG

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Benign Prostatic Hyperplasia Therapeutics Market, by Dosage Form
8.1. Introduction
8.2. Capsule
8.3. Liquid
8.4. Tablet
9. Benign Prostatic Hyperplasia Therapeutics Market, by Distribution Channel
9.1. Introduction
9.2. E-Commerce Platforms
9.3. Hospital Pharmacies
9.4. Retail Pharmacies
10. Benign Prostatic Hyperplasia Therapeutics Market, by End User
10.1. Introduction
10.2. Homecare
10.3. Hospitals
10.4. Urology Clinics
11. Benign Prostatic Hyperplasia Therapeutics Market, by Therapy Type
11.1. Introduction
11.2. 5-Alpha Reductase Inhibitors
11.2.1. Dutasteride
11.2.2. Finasteride
11.3. Alpha Blockers
11.3.1. Alfuzosin
11.3.2. Doxazosin
11.3.3. Tamsulosin
11.3.4. Terazosin
11.4. Combination Therapies
11.4.1. Dutasteride Plus Tamsulosin
11.5. Phytotherapeutics
11.5.1. Beta-Sitosterol
11.5.2. Pygeum
11.5.3. Saw Palmetto
12. Americas Benign Prostatic Hyperplasia Therapeutics Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. AbbVie Inc.
15.3.2. Merck & Co., Inc.
15.3.3. Astellas Pharma Inc.
15.3.4. Johnson & Johnson
15.3.5. Pfizer Inc.
15.3.6. Sanofi S.A.
15.3.7. Bayer AG
15.3.8. Teva Pharmaceutical Industries Ltd.
15.3.9. Sun Pharmaceutical Industries Ltd.
15.3.10. Novartis AG
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET MULTI-CURRENCY
FIGURE 2. BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET MULTI-LANGUAGE
FIGURE 3. BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY LIQUID, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY E-COMMERCE PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY UROLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DUTASTERIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY FINASTERIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALFUZOSIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DOXAZOSIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY TAMSULOSIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY TERAZOSIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DUTASTERIDE PLUS TAMSULOSIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PHYTOTHERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY BETA-SITOSTEROL, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PYGEUM, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY SAW PALMETTO, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PHYTOTHERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PHYTOTHERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PHYTOTHERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 55. CANADA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 56. CANADA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 57. CANADA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 58. CANADA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 59. CANADA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 60. CANADA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 61. CANADA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 62. CANADA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PHYTOTHERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 63. MEXICO BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 64. MEXICO BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. MEXICO BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. MEXICO BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 67. MEXICO BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 68. MEXICO BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 69. MEXICO BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 70. MEXICO BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PHYTOTHERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PHYTOTHERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PHYTOTHERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PHYTOTHERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 96. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 97. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 98. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 100. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 101. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 102. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 103. UNITED KINGDOM BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PHYTOTHERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 104. GERMANY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 105. GERMANY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. GERMANY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. GERMANY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 108. GERMANY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 109. GERMANY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 110. GERMANY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 111. GERMANY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PHYTOTHERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 112. FRANCE BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 113. FRANCE BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. FRANCE BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 115. FRANCE BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 116. FRANCE BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 117. FRANCE BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 118. FRANCE BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 119. FRANCE BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PHYTOTHERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 124. RUSSIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 125. RUSSIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 126. RUSSIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 127. RUSSIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PHYTOTHERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 128. ITALY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 129. ITALY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. ITALY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 131. ITALY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 132. ITALY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 133. ITALY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 134. ITALY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 135. ITALY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PHYTOTHERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 136. SPAIN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 137. SPAIN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. SPAIN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 139. SPAIN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 140. SPAIN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 141. SPAIN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 142. SPAIN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 143. SPAIN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PHYTOTHERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 144. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 145. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 148. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 149. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 150. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 151. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PHYTOTHERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 152. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 153. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 154. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PHYTOTHERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 160. SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 161. SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PHYTOTHERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 168. DENMARK BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 169. DENMARK BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 170. DENMARK BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. DENMARK BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 172. DENMARK BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 173. DENMARK BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 174. DENMARK BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 175. DENMARK BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PHYTOTHERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 176. NETHERLANDS BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 177. NETHERLANDS BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 178. NETHERLANDS BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 179. NETHERLANDS BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 180. NETHERLANDS BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 181. NETHERLANDS BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 182. NETHERLANDS BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 183. NETHERLANDS BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PHYTOTHERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 184. QATAR BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 185. QATAR BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 186. QATAR BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 187. QATAR BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 188. QATAR BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 189. QATAR BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 190. QATAR BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 191. QATAR BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PHYTOTHERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 192. FINLAND BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 193. FINLAND BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 194. FINLAND BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 195. FINLAND BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 196. FINLAND BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 197. FINLAND BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 198. FINLAND BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 199. FINLAND BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PHYTOTHERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 200. SWEDEN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 201. SWEDEN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 202. SWEDEN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 203. SWEDEN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 204. SWEDEN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 205. SWEDEN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 206. SWEDEN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 207. SWEDEN BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PHYTOTHERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 213. NIGERIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 214. NIGERIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 215. NIGERIA BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PHYTOTHERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 216. EGYPT BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 217. EGYPT BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 218. EGYPT BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 219. EGYPT BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 220. EGYPT BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 221. EGYPT BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 222. EGYPT BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 223. EGYPT BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PHYTOTHERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 224. TURKEY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 225. TURKEY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 226. TURKEY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 227. TURKEY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 228. TURKEY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 229. TURKEY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 230. TURKEY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 231. TURKEY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PHYTOTHERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 232. ISRAEL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 233. ISRAEL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 234. ISRAEL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 235. ISRAEL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 236. ISRAEL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 237. ISRAEL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 238. ISRAEL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 239. ISRAEL BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PHYTOTHERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 240. NORWAY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 241. NORWAY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 242. NORWAY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 243. NORWAY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 244. NORWAY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 245. NORWAY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 246. NORWAY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 247. NORWAY BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PHYTOTHERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 248. POLAND BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 249. POLAND BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 250. POLAND BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 251. POLAND BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 252. POLAND BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 253. POLAND BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 254. POLAND BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 255. POLAND BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PHYTOTHERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 256. SWITZERLAND BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 257. SWITZERLAND BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 258. SWITZERLAND BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PHYTOTHERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 264. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 265. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 266. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 267. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 268. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 269. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 270. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2030 (USD MILLION)
TABLE 271. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SIZE, BY PHYTOTHERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 272. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SI

Companies Mentioned

The companies profiled in this Benign Prostatic Hyperplasia Therapeutics market report include:
  • AbbVie Inc.
  • Merck & Co., Inc.
  • Astellas Pharma Inc.
  • Johnson & Johnson
  • Pfizer Inc.
  • Sanofi S.A.
  • Bayer AG
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Novartis AG

Methodology

Loading
LOADING...

Related Topics

Related Reports

Benign Prostatic Hyperplasia Treatment Market by Treatment Type, Product Type, End User - Global Forecast to 2030 - Product Image

Benign Prostatic Hyperplasia Treatment Market by Treatment Type, Product Type, End User - Global Forecast to 2030

  • Report
  • 185 Pages
  • Global
From
Benign Prostatic Hyperplasia Treatment Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type - Product Image

Benign Prostatic Hyperplasia Treatment Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

  • Report
  • 96 Pages
  • Global
From
Benign Prostatic Hyperplasia Treatment Global Market Report 2025 - Product Image

Benign Prostatic Hyperplasia Treatment Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Benign Prostatic Hyperplasia Treatment Market Report by Treatment Type, and Region 2024-2032 - Product Image

Benign Prostatic Hyperplasia Treatment Market Report by Treatment Type, and Region 2024-2032

  • Report
  • 148 Pages
  • Global
From
Benign Prostatic Hyperplasia Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Benign Prostatic Hyperplasia Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 97 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.